Assembly Financial Statements From 2010 to 2024

ASMB Stock  USD 15.04  0.32  2.17%   
Assembly Biosciences financial statements provide useful quarterly and yearly information to potential Assembly Biosciences investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Assembly Biosciences financial statements helps investors assess Assembly Biosciences' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Assembly Biosciences' valuation are summarized below:
Gross Profit
-63.9 M
Profit Margin
(2.12)
Market Capitalization
95.6 M
Enterprise Value Revenue
0.0737
Revenue
21.5 M
We have found one hundred twenty available fundamental signals for Assembly Biosciences, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of Assembly Biosciences prevailing market performance against the performance between 2010 and 2024 to make sure the company can sustain itself down the road. As of November 25, 2024, Market Cap is expected to decline to about 38.5 M. In addition to that, Enterprise Value is expected to decline to about 23.5 M

Assembly Biosciences Total Revenue

11.2 Million

Check Assembly Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Assembly Biosciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 251.4 K, Interest Expense of 544.1 K or Selling General Administrative of 17.7 M, as well as many indicators such as Price To Sales Ratio of 6.87, Dividend Yield of 0.0 or PTB Ratio of 1.04. Assembly financial statements analysis is a perfect complement when working with Assembly Biosciences Valuation or Volatility modules.
  
Check out the analysis of Assembly Biosciences Correlation against competitors.
For information on how to trade Assembly Stock refer to our How to Trade Assembly Stock guide.

Assembly Biosciences Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets130.2 M137.5 M134 M
Slightly volatile
Short and Long Term Debt Total2.2 M2.3 M9.4 M
Slightly volatile
Other Current LiabilitiesM6.6 M5.1 M
Slightly volatile
Total Current Liabilities41.2 M39.2 M14.5 M
Slightly volatile
Property Plant And Equipment NetM2.7 M2.9 M
Slightly volatile
Accounts Payable437.9 K461 K2.3 M
Pretty Stable
Cash36.5 M19.8 M36.9 M
Slightly volatile
Non Current Assets Total3.5 M3.7 M27.2 M
Pretty Stable
Non Currrent Assets Other296.4 K312 KM
Slightly volatile
Cash And Short Term Investments99.4 M130.2 M102 M
Slightly volatile
Common Stock Total Equity59.2 K56.4 K27.8 K
Slightly volatile
Common Stock Shares Outstanding4.3 M4.6 M12.7 M
Slightly volatile
Liabilities And Stockholders Equity130.2 M137.5 M134 M
Slightly volatile
Non Current Liabilities Total62.5 M57.1 M142 M
Slightly volatile
Other Current Assets3.4 M6.7 M3.5 M
Slightly volatile
Other Stockholder Equity868.3 M826.9 M453 M
Slightly volatile
Total Liabilities101.2 M96.4 M35.1 M
Slightly volatile
Property Plant And Equipment GrossM2.9 M2.9 M
Slightly volatile
Total Current Assets102.4 M133.8 M105.1 M
Slightly volatile
Short Term Debt1.2 M1.2 M3.4 M
Slightly volatile
Common Stock4.8 KK20.6 K
Slightly volatile
Property Plant EquipmentM854.5 KM
Slightly volatile
Net Tangible Assets107.5 M95.1 M94 M
Slightly volatile
Capital Surpluse975.6 M929.1 M474 M
Slightly volatile
Other Liabilities2.3 M2.5 M14.5 M
Pretty Stable
Current Deferred Revenue32.5 M30.9 M8.7 M
Slightly volatile
Net Receivables40.9 K43 K1.8 M
Slightly volatile
Net Invested Capital39 M41.1 M130.7 M
Very volatile
Net Working Capital124 M94.6 M131.8 M
Pretty Stable
Capital Stock4.8 KK26.5 K
Very volatile
Capital Lease Obligations2.2 M2.3 M9.8 M
Slightly volatile

Assembly Biosciences Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization251.4 K450 K259.2 K
Slightly volatile
Selling General Administrative17.7 M22.9 M18.1 M
Slightly volatile
Other Operating Expenses61 M71.8 M62.7 M
Slightly volatile
Research Development43.3 M48.9 M44.5 M
Slightly volatile
Total Operating Expenses21.8 M22.9 M56.8 M
Slightly volatile
Net Interest Income1.6 M2.4 M1.8 M
Pretty Stable
Interest Income1.6 M2.4 M1.8 M
Pretty Stable
Reconciled Depreciation550.2 K490 K372.4 K
Slightly volatile
Extraordinary Items6.9 M7.7 M8.4 M
Slightly volatile
Selling And Marketing Expenses360 K405 K441 K
Slightly volatile

Assembly Biosciences Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based CompensationM5.1 M9.2 M
Slightly volatile
Begin Period Cash Flow35.3 M52.4 M36.6 M
Slightly volatile
Other Cashflows From Financing Activities122.5 K129 K17.7 M
Pretty Stable
Depreciation251.4 K450 K259.2 K
Slightly volatile
Capital Expenditures242.2 K255 K603.5 K
Slightly volatile
Total Cash From Financing Activities13.1 M13.8 M42.2 M
Very volatile
End Period Cash Flow36.5 M19.8 M36.9 M
Slightly volatile
Sale Purchase Of Stock670.8 K706.1 K40.3 M
Pretty Stable
Net Borrowings494.7 K552.1 K477.7 K
Slightly volatile
Change To Netincome15.8 M11.6 M13.5 M
Slightly volatile
Issuance Of Capital Stock4.6 M4.9 M106.8 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio6.877.23651
Slightly volatile
Days Sales Outstanding2.392.5260.38
Slightly volatile
Average Payables1.2 MM1.8 M
Slightly volatile
Stock Based Compensation To Revenue1.10.820.9727
Very volatile
Capex To Depreciation0.540.56672.7152
Pretty Stable
EV To Sales4.24.42645
Slightly volatile
Days Of Inventory On Hand0.00.01.0E-4
Slightly volatile
Payables Turnover11110617.2492
Slightly volatile
Sales General And Administrative To Revenue1.942.882.1733
Slightly volatile
Average Inventory0.420.580.4667
Pretty Stable
Research And Ddevelopement To Revenue4.586.145.2913
Pretty Stable
Capex To Revenue0.03040.0320.1006
Very volatile
Cash Per Share17.0728.45459.7971
Slightly volatile
Days Payables Outstanding3.273.4415.6 K
Slightly volatile
Current Ratio3.243.410810.1425
Slightly volatile
Receivables Turnover15715039.9599
Slightly volatile
Graham Number49.3851.982368.3631
Slightly volatile
Capex Per Share0.05850.05570.0298
Slightly volatile
Revenue Per Share1.481.410.7835
Slightly volatile
Interest Debt Per Share0.910.966.1082
Slightly volatile
Debt To Assets0.03610.0380.4578
Slightly volatile
Operating Cycle2.392.5260.38
Slightly volatile
Days Of Payables Outstanding3.273.4415.6 K
Slightly volatile
Ebt Per Ebit0.90.9466213.9 K
Slightly volatile
Quick Ratio3.243.410810.1425
Slightly volatile
Net Income Per E B T0.621.00050.8207
Slightly volatile
Cash Ratio0.480.50586.1152
Slightly volatile
Days Of Inventory Outstanding0.00.01.0E-4
Slightly volatile
Days Of Sales Outstanding2.392.5260.38
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.080.98880.9811
Very volatile
Fixed Asset Turnover2.873.028.5593
Slightly volatile
Debt Ratio0.03610.0380.4578
Slightly volatile
Price Sales Ratio6.877.23651
Slightly volatile
Asset Turnover0.06930.04690.0672
Pretty Stable

Assembly Biosciences Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap38.5 M40.5 M2.5 B
Very volatile
Enterprise Value23.5 M24.8 M2.4 B
Very volatile

Assembly Fundamental Market Drivers

Cash And Short Term Investments130.2 M

Assembly Upcoming Events

27th of March 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Assembly Biosciences Financial Statements

Assembly Biosciences stakeholders use historical fundamental indicators, such as Assembly Biosciences' revenue or net income, to determine how well the company is positioned to perform in the future. Although Assembly Biosciences investors may analyze each financial statement separately, they are all interrelated. For example, changes in Assembly Biosciences' assets and liabilities are reflected in the revenues and expenses on Assembly Biosciences' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Assembly Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue30.9 M32.5 M
Total Revenue7.2 M11.2 M
Cost Of Revenue48.9 M51.3 M
Stock Based Compensation To Revenue 0.82  1.10 
Sales General And Administrative To Revenue 2.88  1.94 
Research And Ddevelopement To Revenue 6.14  4.58 
Capex To Revenue 0.03  0.03 
Revenue Per Share 1.41  1.48 
Ebit Per Revenue(10.38)(10.90)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Assembly Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Assembly Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Assembly Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Assembly Biosciences Stock:
Check out the analysis of Assembly Biosciences Correlation against competitors.
For information on how to trade Assembly Stock refer to our How to Trade Assembly Stock guide.
You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Assembly Biosciences. If investors know Assembly will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Assembly Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(6.89)
Revenue Per Share
4.125
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.35)
Return On Equity
(1.02)
The market value of Assembly Biosciences is measured differently than its book value, which is the value of Assembly that is recorded on the company's balance sheet. Investors also form their own opinion of Assembly Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Assembly Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Assembly Biosciences' market value can be influenced by many factors that don't directly affect Assembly Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Assembly Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Assembly Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Assembly Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.